CLINICAL STUDIES
Amiodarone reduces transmural heterogeneity of repolarization in the human heart
Emmanuel Drouin, PhD*,
Gilles Lande, MD and
Flavien Charpentier, PhD
* Department of Neonatology, Centre Hôpitalier Universitaire de Nantes, Nantes, France
Department of Cardiology, Centre Hôpitalier Universitaire de Nantes, Nantes, France
Laboratoire de Physiopathologie et Pharmacologie Cellulaires et Moléculaires INSERM CJF96-01, Centre Hôspitalo-Universitaire de Nantes, Nantes, France
Manuscript received March 5, 1997;
revised manuscript received April 15, 1998,
accepted June 12, 1998.
Address for correspondence: Dr. Emmanuel Drouin, Department of Neonatology, Hôpital Mère & Enfant, Centre Hôspitalo-Universitaire de Nantes, 10 quai Moncousu, 44093 Nantes Cedex 01, France
Objectives. The present work was designed to test the effects of amiodarone therapy on action potential characteristics of the three cell types observed in human left ventricular preparations.
Background. The electrophysiologic basis for amiodarone’s exceptional antiarrhythmic efficacy and low proarrhythmic profile remains unclear.
Methods. We used standard microelectrode techniques to investigate the effects of chronic amiodarone therapy on transmembrane activity of the three predominant cellular subtypes (epicardial, midmyocardial [M] and endocardial cells) spanning the human left ventricle in hearts explanted from normal, heart failure and amiodarone-treated heart failure patients.
Results. Tissues isolated from the ventricles of heart failure patients receiving chronic amiodarone therapy displayed M cell action potential duration (404 ± 12 ms) significantly briefer (p < 0.05) than that recorded in tissues isolated from normal hearts (439 ± 22 ms) or from heart failure patients not treated with amiodarone (449 ± 18 ms). Endocardial cells from amiodarone-treated heart failure patients displayed longer (p < 0.05) action potential duration (363 ± 10 ms) than endocardial cells isolated from normal hearts (330 ± 6 ms). As a consequence, the heterogeneity of ventricular repolarization in tissues from patients treated with amiodarone was considerably smaller than in the two other groups, especially at long pacing cycle lengths.
Conclusions. These findings may explain, at least in part, the reduction of ventricular repolarization dispersion and the lower incidence of torsade de pointes observed with chronic amiodarone therapy as compared with other class III agents.
|
Abbreviations and Acronyms
| | AM | = group of patients treated with amiodarone | | APD | = action potential duration | | EAD | = early afterdepolarization | | ECG | = electrocardiogram | | HF | = group of patients with heart failure | | NH | = group of patients with normal heart | | PCL | = pacing cycle length | | TdP | = torsade de pointes | | Vmax | = maximal rate of rise of phase 0 of the action potential |
|
This article has been cited by other articles:
|
|
|
|
 
K. H. W. J. ten Tusscher and A. V. Panfilov
Alternans and spiral breakup in a human ventricular tissue model
Am J Physiol Heart Circ Physiol,
September 1, 2006;
291(3):
H1088 - H1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Fish, J. M. Di Diego, V. Nesterenko, and C. Antzelevitch
Epicardial Activation of Left Ventricular Wall Prolongs QT Interval and Transmural Dispersion of Repolarization: Implications for Biventricular Pacing
Circulation,
May 4, 2004;
109(17):
2136 - 2142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. W. J. ten Tusscher, D. Noble, P. J. Noble, and A. V. Panfilov
A model for human ventricular tissue
Am J Physiol Heart Circ Physiol,
April 1, 2004;
286(4):
H1573 - H1589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al.
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2004;
9(1_suppl):
S65 - S83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. N. Singh and N. Wadhani
Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2004;
9(1_suppl):
S85 - S97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Huang, J. L. Skinner, J. M. Rogers, W. M. Smith, W. L. Holman, and R. E. Ideker
The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs
J. Am. Coll. Cardiol.,
July 17, 2002;
40(2):
375 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. van Opstal, M. Schoenmakers, S. C. Verduyn, S.H. M. de Groot, J. D.M. Leunissen, F. F. van der Hulst, M. M.C. Molenschot, H. J.J. Wellens, and M. A. Vos
Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome
Circulation,
November 27, 2001;
104(22):
2722 - 2727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Pereon, S. Demolombe, I. Baro, E. Drouin, F. Charpentier, and D. Escande
Differential expression of KvLQT1 isoforms across the human ventricular wall
Am J Physiol Heart Circ Physiol,
June 1, 2000;
278(6):
H1908 - H1915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Stankovicova, M. Szilard, I De Scheerder, and K. R Sipido
M cells and transmural heterogeneity of action potential configuration in myocytes from the left ventricular wall of the pig heart
Cardiovasc Res,
March 1, 2000;
45(4):
952 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Merot, F. Charpentier, J.-M. Poirier, G. Coutris, and J. Weissenburger
Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol
Cardiovasc Res,
November 1, 1999;
44(2):
303 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
